{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:11:21Z","timestamp":1778901081144,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vasdi.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:38:17Z","timestamp":1772195897000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer treatment-related ischemic arterial events: Focus on peripheral arterial disease and cerebrovascular events"],"prefix":"10.1016","volume":"51","author":[{"given":"Gilles","family":"Pernod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Sarlon-Bartoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Antoinette","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vasdi.2026.02.006_bib0280","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.acvd.2023.11.007","article-title":"Cancer-related arterial thromboembolic events","volume":"117","author":"Pernod","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0285","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0290","first-page":"e553","article-title":"Overview of FDA-approved anti-cancer drugs used for targeted therapy","volume":"2","author":"Di Martino","year":"2015","journal-title":"World Cancer Res J"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0295","doi-asserted-by":"crossref","first-page":"36441","DOI":"10.1039\/D5RA05472A","article-title":"Medicinal chemistry perspectives on anticancer drug design based on clinical applications (2015\u20132025)","volume":"15","author":"Al-Karmalawy","year":"2025","journal-title":"RSC Adv"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0300","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0420","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0350","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"16","author":"Haguet","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0305","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0310","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0315","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","article-title":"Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial","volume":"14","author":"Cameron","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0320","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0325","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/JCMA.0000000000001026","article-title":"Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: a systemic review and network meta-analysis","volume":"87","author":"Chen","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0330","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0335","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0430","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0465","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer","volume":"9","author":"Saphner","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0485","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities","volume":"77","author":"Lu-Yao","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","article-title":"Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies","volume":"99","author":"Du","year":"2025","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0355","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0360","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0365","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0370","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0375","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-020-04392-w","article-title":"Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib","volume":"100","author":"Caocci","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0380","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease andother vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Magro","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0390","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European Leukemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0395","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0400","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0405","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0410","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-023-05556-0","article-title":"The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib","volume":"103","author":"Mulas","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0415","first-page":"66","article-title":"Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia","volume":"46","author":"Sarlon-Bartoli","year":"2021","journal-title":"J Med Vasc"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0425","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0440","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0445","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0450","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0455","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1161\/CIRCULATIONAHA.124.070432","article-title":"Cardiovascular complications and their association with short-and long-term outcomes in patients with multiple myeloma and lymphoma undergoing chimeric antigen receptor T-cell therapy","volume":"150","author":"Itzhaki Ben Zadok","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0460","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.70216","article-title":"Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy","volume":"208","author":"Itzhaki Ben Zadok","year":"2026","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0470","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","article-title":"Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial","volume":"7","author":"Buzdar","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0475","doi-asserted-by":"crossref","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0480","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0490","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0495","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/hed.26102","article-title":"Prevalence of carotid stenosis following radiotherapy for head and neck cancer: a systematic review and meta-analysis","volume":"42","author":"Texakalidis","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0500","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00415-024-12197-4","article-title":"Progression rate of radiation-induced carotid stenosis in head and neck cancer survivors after statin treatment: a retrospective cohort study","volume":"271","author":"Chen","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0505","first-page":"563","article-title":"Radiation-induced peripheral artery disease","volume":"72","author":"Jurado","year":"2008","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0510","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0515","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/gyno.2001.6525","article-title":"Iliac atherosclerotic occlusive disease complicating radiation therapy for cervix cancer: a case series","volume":"84","author":"Moutardier","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0520","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0525","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0530","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for therapeutic radiology and oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0535","first-page":"1","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"00","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0540","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0545","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bulcan.2015.11.008","article-title":"Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques","volume":"103","author":"Rea","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.vasdi.2026.02.006_bib0550","doi-asserted-by":"crossref","first-page":"e0246684","DOI":"10.1371\/journal.pone.0246684","article-title":"Total plaque score helps to determine follow-up strategy for carotid artery stenosis progression in head and neck cancer patients after radiation therapy","volume":"16","author":"Liu","year":"2021","journal-title":"PLoS One"}],"container-title":["Vascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658126001780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050658126001780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:25:16Z","timestamp":1778898316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050658126001780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050658126001780"],"URL":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.02.006","relation":{},"ISSN":["3050-6581"],"issn-type":[{"value":"3050-6581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer treatment-related ischemic arterial events: Focus on peripheral arterial disease and cerebrovascular events","name":"articletitle","label":"Article Title"},{"value":"Vascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vasdi.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}